PT-141: The Peptide That Re-Wires the Brain for Intimacy and Desire

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is PT-141 (Bremelanotide) and What Does It Do?

PT-141, known generically as bremelanotide, is a synthetic peptide therapy derived from melanotan II. It was developed to address a complex and often misunderstood aspect of sexual health: desire. In June 2019, PT-141 received FDA approval under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.¹

HSDD is characterized by a persistent deficiency or absence of sexual fantasies and desire, resulting in significant personal distress. Unlike treatments that target blood flow or physical arousal, PT-141 was designed to target the neurological pathways involved in sexual motivation and desire.²

Fast Facts

How Does PT-141 Work for Sexual Desire?

Unlike traditional medications that work peripherally to increase blood flow (like sildenafil or tadalafil), the PT-141 peptide operates entirely differently. It goes straight to the source of desire: the central nervous system.

1. The Melanocortin Switch PT-141 is a non-selective agonist of melanocortin receptors, but its primary effect on sexual desire comes from activating the MC4R receptor. It acts directly on presynaptic MC4R neurons in the hypothalamus, which is the brain’s command center for regulating sexual behavior and arousal.^3,4

2. The Dopamine Response When these receptors are activated, they stimulate the release of dopamine into several key regions of the brain, including the nucleus accumbens and the amygdala. These areas are critical for motivation, reward, and emotional processing.^{4, 5}

3. Targeting Desire Over Mechanics By engaging these specific neural pathways, PT-141 addresses the motivational and desire-driven aspects of sexual behavior. It isn’t just about the physical mechanics of arousal; it’s about restoring the psychological drive and desire that start the process.⁵

The efficacy and safety of bremelanotide were primarily established in the RECONNECT Phase 3 clinical trials, which focused on premenopausal women with acquired, generalized HSDD. Those trials demonstrated that PT-141 was associated with significant improvements in the Female Sexual Function Index desire domain and reductions in the Female Sexual Distress Scale scores compared to placebo.¹ The 52-week open-label extension study, published by Simon et al., further supported these findings, noting that the peptide therapy maintained efficacy and safety over an extended period.²

These results highlight the potential of targeting the melanocortin receptor system as a viable strategy for HSDD treatment, offering a meaningful option for patients who experience distress related to low sexual desire. Researchers continue to explore the broader applications of this HSDD treatment approach.³

While the bremelanotide peptide has been shown to be effective for its approved indication, it’s associated with specific side effects. The most commonly reported side effect in clinical trials was nausea, which affected about 40% of participants. Other reported side effects included flushing and headache.¹

Because it activates the MC4R receptor, PT-141 can cause transient increases in blood pressure and decreases in heart rate. These changes typically peak within 4 hours and return to baseline by 8-10 hours. Due to these effects, individuals with uncontrolled hypertension or known cardiovascular disease should not take PT-141.^3,6

Scientific References

1. Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for treatment of female hypoactive sexual desire. Neurol Int.2022;14(1):75-88.
2. Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.Obstet Gynecol.2019;134(5):909-917.
3. Mayer D, Lynch SE. Bremelanotide: new drug approved for treating hypoactive sexual desire disorder. Ann Pharmacother.2020;54(7):684-690.
4. Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med.2007;4(Suppl 4):269-279.
5. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem.2007;7(11):1137-1144.
6. US Food and Drug Administration. Vyleesi (bremelanotide) injection, for subcutaneous use: prescribing information. Revised June 2019. Accessed September 29, 2026.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io. 

FAQ

What Is PT-141 (Bremelanotide) and What Does It Do?

PT-141 is another name for bremelanotide, a synthetic peptide that acts on melanocortin receptors in the central nervous system. Rather than working mainly through blood flow, PT-141 is designed to influence brain pathways related to sexual desire and motivation. The FDA-approved bremelanotide product is sold under the brand name Vyleesi.

Is PT-141 FDA Approved, and Who Is It Approved For?

Yes, but only in a specific form and for a specific group. The FDA approved Vyleesi, which contains bremelanotide, for premenopausal women with acquired, generalized HSDD, meaning low sexual desire that causes significant distress and is not explained by another medical condition, relationship problem, or medicine. PT-141 is not FDA approved for men, postmenopausal women, erectile dysfunction, or sexual-performance enhancement.

What Are the Potential PT-141 Benefits for Women?

In two large Phase 3 trials, bremelanotide was associated with improvements in sexual desire and lower sexual distress compared with placebo among premenopausal women with acquired, generalized HSDD. An open-label extension study followed participants for longer and reported continued findings on safety and effectiveness. These results apply to the studied HSDD population, not to every cause of low libido.

Is PT-141 Nasal Spray FDA Approved?

No. The FDA-approved bremelanotide product is Vyleesi, which is supplied as a prefilled, single-dose product for its approved indication. A PT-141 nasal spray is not the FDA-approved Vyleesi product, so it should not be described as FDA approved simply because bremelanotide has an approved use. A licensed provider can help explain the difference between an approved drug and another formulation.

What Should You Know About PT-141 Dosage for Women and Men?

The FDA label provides dosing information for Vyleesi only in its approved population: premenopausal women with acquired, generalized HSDD. It does not establish an FDA-approved PT-141 dosage for men, for nasal sprays, or for other unapproved formulations. Online PT-141 dosage charts and calculators cannot account for a person’s health history, blood pressure, other medicines, or whether the product itself is appropriate. A qualified prescriber should determine whether treatment is suitable and how it should be monitored.

Is PT-141 Better Than Sildenafil (Viagra)?

PT-141 and sildenafil are not direct substitutes, so neither is universally “better.” PT-141, also called bremelanotide, acts on brain pathways involved in desire and is FDA approved for a specific form of low sexual desire in premenopausal women. Sildenafil, sold as Viagra, is a PDE5 inhibitor approved for erectile dysfunction. It supports blood flow needed for an erection, but it does not create sexual desire and requires sexual stimulation to work.

Find a provider